Bain Capital Life Sciences Investors’s ARYA Sciences Acquisition Corp V Class A Ordinary Shares ARYE Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio ARYE Stock Details ARYE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500,000	Closed	-$4.91M	–	35
2022 Q3	$4.91M	Hold	500,000	–	–	0.59%	27
2022 Q2	$4.86M	Hold	500,000	–	–	0.57%	31
2022 Q1	$4.86M	Hold	500,000	–	–	0.47%	30
2021 Q4	$4.85M	Hold	500,000	–	–	0.38%	28
2021 Q3	$4.94M	Buy	+500,000	New	+$4.97M	0.31%	27

Other funds holding ARYE

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.44% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bain Capital Life Sciences Investors's ARYE Position: Q4 2022 in Review

Bain Capital Life Sciences Investors sold out of ARYA Sciences Acquisition Corp V Class A Ordinary Shares (ARYE) in Q4 2022, closing a stake of 500,000 shares — an estimated $4.91M sold.

Bain Capital Life Sciences Investors first reported a position in ARYE in Q3 2021 and held it in 5 quarters. The position peaked at $4.94M in Q3 2021. 50 funds tracked by Wall St. Rank hold ARYE as of Q4 2022.

Bain Capital Life Sciences Investors reported no remaining ARYA Sciences Acquisition Corp V Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 500,000 ARYA Sciences Acquisition Corp V Class A Ordinary Shares shares in Q4 2022, an estimated $4.91M.
Bain Capital Life Sciences Investors first reported a position in ARYA Sciences Acquisition Corp V Class A Ordinary Shares in Q3 2021 and held it in 5 quarters.
Bain Capital Life Sciences Investors's ARYA Sciences Acquisition Corp V Class A Ordinary Shares position peaked at $4.94M in Q3 2021.
50 funds tracked by Wall St. Rank held ARYA Sciences Acquisition Corp V Class A Ordinary Shares as of Q4 2022.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2022, filed 14 Feb 2023.